MaryamFouladiMD

Clinical Trials

• Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Start of enrollment: 2002 Oct 01

  Completed

  Phase 2

• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Start of enrollment: 2002 Sep 01

  Completed

  Phase 1

• Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Start of enrollment: 2003 Nov 01

  Completed

  Phase 2

• Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Start of enrollment: 2004 Oct 01

  Completed

  Phase 1, Phase 2

• Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia Start of enrollment: 2005 Aug 01

  Completed

  Phase 1

• MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer Start of enrollment: 2008 Jul 01

  Terminated

  Phase 1

• Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System Start of enrollment: 2009 Feb 25

  Completed

  Phase 1

• Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment Start of enrollment: 2009 Apr 01

  Completed

  Phase 1

• A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas Start of enrollment: 2009 May 01

  Completed

  Early Phase 1

• Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Start of enrollment: 2010 Apr 19

  Active, not recruiting

  Phase 1, Phase 2

• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Start of enrollment: 2011 Jan 01

  Completed

  Phase 1

• Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Start of enrollment: 2011 Jan 26

  Completed

  Phase 2, Phase 3

• Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas Start of enrollment: 2012 Feb 01

  Completed

  Phase 1, Phase 2

• p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors Start of enrollment: 2013 Aug 01

  Completed

  Phase 1

• Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Start of enrollment: 2015 Jul 14

  Completed

  Phase 1

• Panobinostat in Treating Younger Patients With Progressive Diffuse Intrinsic Pontine Glioma Start of enrollment: 2016 Apr 01
• International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository Start of enrollment: 2012 Jun 01

  Recruiting

• ONC201 in Pediatric H3 K27M Gliomas Start of enrollment: 2018 Jan 29

  Active, not recruiting

  Phase 1

• A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma Start of enrollment: 2018 Aug 01

  Active, not recruiting

  Phase 1

• A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion Start of enrollment: 2021 Apr 08

  Recruiting

  Early Phase 1

• A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) Start of enrollment: 2021 May 24

  Recruiting

  Phase 1

• Join now to see all